Search Page

1

Cite

Share

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH. Meulendijks D, et al. Among authors: deenen mj. Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23. Lancet Oncol. 2015. PMID: 26603945 Review.

Cite

Share

2

Cite

Share

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.

Hulshof EC, Deenen MJ, Guchelaar HJ, Gelderblom H. Hulshof EC, et al. Among authors: deenen mj. Eur J Cancer. 2020 Dec;141:9-20. doi: 10.1016/j.ejca.2020.09.007. Epub 2020 Oct 23. Eur J Cancer. 2020. PMID: 33125947 Free article. Review.

Cite

Share

3

Cite

Share

ASO Author Reflection: Systemic Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy with Oxaliplatin in Patients with Colorectal Peritoneal Metastases.

Lurvink RJ, Rovers KP, de Hingh IHJT, Deenen MJ. Lurvink RJ, et al. Among authors: deenen mj. Ann Surg Oncol. 2020 Dec;27(Suppl 3):799-800. doi: 10.1245/s10434-020-08780-4. Epub 2020 Jun 29. Ann Surg Oncol. 2020. PMID: 32602062 No abstract available.

Cite

Share

4

Cite

Share

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Deenen MJ, Cats A, Beijnen JH, Schellens JH. Deenen MJ, et al. Oncologist. 2011;16(6):811-9. doi: 10.1634/theoncologist.2010-0258. Epub 2011 May 31. Oncologist. 2011. PMID: 21632456 Free PMC article. Review.

Cite

Share

5

Cite

Share

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

Deenen MJ, Cats A, Beijnen JH, Schellens JH. Deenen MJ, et al. Oncologist. 2011;16(7):1006-20. doi: 10.1634/theoncologist.2010-0261. Epub 2011 Jun 9. Oncologist. 2011. PMID: 21659612 Free PMC article. Review.

Cite

Share

6

Cite

Share

Reply to T. Magnes et al.

Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH. Deenen MJ, et al. J Clin Oncol. 2016 Jul 10;34(20):2434-5. doi: 10.1200/JCO.2016.67.4374. Epub 2016 May 9. J Clin Oncol. 2016. PMID: 27161961 No abstract available.

Cite

Share

7

Cite

Share

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

Deenen MJ, Cats A, Beijnen JH, Schellens JH. Deenen MJ, et al. Oncologist. 2011;16(7):992-1005. doi: 10.1634/theoncologist.2010-0260. Epub 2011 Jun 9. Oncologist. 2011. PMID: 21659608 Free PMC article. Review.

Cite

Share

8

Cite

Share

Is vancomycin clearance really correlated with hemoglobin? Arguments that it's not.

Deenen MJ, Ter Heine R. Deenen MJ, et al. Eur J Clin Pharmacol. 2019 Nov;75(11):1617-1618. doi: 10.1007/s00228-019-02724-y. Epub 2019 Jul 27. Eur J Clin Pharmacol. 2019. PMID: 31352558 No abstract available.

Cite

Share

9

Cite

Share

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, Gelderblom H. Lunenburg CATC, et al. Among authors: deenen mj. Eur J Cancer. 2016 Feb;54:40-48. doi: 10.1016/j.ejca.2015.11.008. Epub 2015 Dec 21. Eur J Cancer. 2016. PMID: 26716401 Review.

Cite

Share

10

Cite

Share

The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults.

Bury D, Ter Heine R, van de Garde EMW, Nijziel MR, Grouls RJ, Deenen MJ. Bury D, et al. Among authors: deenen mj. Eur J Clin Pharmacol. 2019 Jul;75(7):921-928. doi: 10.1007/s00228-019-02657-6. Epub 2019 Mar 15. Eur J Clin Pharmacol. 2019. PMID: 30877327

Cite

Share